Clinical Trial Update: BAY88-8223, Does Response Study in HRPC Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for BAY88-8223 in hormone-refractory prostate cancer with bone metastases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Hormone-refractory Prostate Cancer

Drugs mentioned

• BAY88-8223

Snippet

Sponsor: Bayer | Conditions: Hormone Refractory Prostate Cancer, Bone Metastases | Phase 2 | Status: COMPLETED